Audentes Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016
Net loss
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on investments
Depreciation and amortization
Stock-based compensation
Deferred income taxes
(Accretion of discount) amortization of premium on investments
Accretion of asset retirement obligation
Change in fair value of contingent acquisition consideration payable
Other
Changes in operating assets and liabilities:
Additions to restricted cash
Restricted cash
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Deferred rent
Cash acquired from acquisition
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Proceeds from sales of property and equipment
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Proceeds from exercise of stock options
Proceeds from issuance of convertible preferred stock, net of issuance costs
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from exercise of stock options and purchases of common stock under employee stock purchase plan
Proceeds from issuance of common stock, net of offering costs
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Net cash provided by financing activities
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Noncash investing and financing activities:
Change in accounts payable, accrued liabilities and facility lease obligations related to property and equipment purchases
Issuance of common stock warrant related to debt financing facility
Conversion of redeemable convertible preferred stock to common stock at closing of initial public offering
Net assets acquired and stock issued for the Cardiogen acquisition
Preferred stock issuance costs
Issuance of common stock in exchange for license
Deferred financing costs for public offerings

Comments